NDAINTRAMUSCULARSOLUTION
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
SEIZALAM (midazolam hydrochloride) by Medcaptain Medical Technology is short-acting benzodiazepine central nervous system (cns) depressant. First approved in 2018.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEIZALAM is a short-acting benzodiazepine CNS depressant administered intramuscularly as a solution for acute seizure management. Midazolam hydrochloride works by enhancing inhibitory neurotransmission in the central nervous system. The product targets emergency and acute care settings where rapid seizure control is critical.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable market position and established commercial infrastructure supporting mid-sized brand teams.
Mechanism of Action
short-acting benzodiazepine central nervous system (CNS) depressant.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
Started Apr 2018
3 enrolled
Nervous System Diseases
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
Started Oct 2017
25 enrolled
Nervous System Diseases
Career Relevance
SEIZALAM offers career opportunities primarily in commercial execution, government affairs, and market access—areas critical for defending a branded small molecule in a competitive, generic-heavy landscape. Roles emphasize hospital formulary relationships, payer negotiations, and clinical adoption in emergency medicine networks rather than discovery or early development.
Worked on SEIZALAM at Medcaptain Medical Technology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.